{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:54:32Z","timestamp":1782604472444,"version":"3.54.5"},"reference-count":95,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T00:00:00Z","timestamp":1185926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2007,8]]},"DOI":"10.1016\/j.cld.2007.06.010","type":"journal-article","created":{"date-parts":[[2007,8,27]],"date-time":"2007-08-27T11:10:10Z","timestamp":1188213010000},"page":"597-613","source":"Crossref","is-referenced-by-count":125,"title":["Lipid-Lowering Agents That Cause Drug-Induced Hepatotoxicity"],"prefix":"10.1016","volume":"11","author":[{"given":"Sidharth S.","family":"Bhardwaj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naga","family":"Chalasani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cld.2007.06.010_bib1","unstructured":"American Heart Association. Cardiovascular disease statistics. 2006. Available at: http:\/\/www.americanheart.org\/presenter.jhtml?identifier=4478. Accessed January 1, 2007."},{"key":"10.1016\/j.cld.2007.06.010_bib2","unstructured":"British Heart Foundation statistics website. CVD mortality in Europe. 2005. Available at: http:\/\/www.heartstats.org\/topic.asp?id=753. Accessed January 1, 2007."},{"issue":"3","key":"10.1016\/j.cld.2007.06.010_bib3","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jacc.2004.07.001","article-title":"Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines","volume":"44","author":"Grundy","year":"2004","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.cld.2007.06.010_bib4","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1089-3261(03)00024-2","article-title":"Hepatotoxicity of hypolipidemic drugs","volume":"7","author":"Parra","year":"2003","journal-title":"Clin Liver Dis"},{"issue":"2","key":"10.1016\/j.cld.2007.06.010_bib5","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1055\/s-2002-30102","article-title":"Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs","volume":"22","author":"Chitturi","year":"2002","journal-title":"Semin Liver Dis"},{"issue":"5","key":"10.1016\/j.cld.2007.06.010_bib6","first-page":"25","article-title":"[Mechanisms of hepatotoxicity]","volume":"85","author":"Bertolami","year":"2005","journal-title":"Arq Bras Cardiol"},{"issue":"7","key":"10.1016\/j.cld.2007.06.010_bib7","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.cgh.2006.04.014","article-title":"Severe hepatic side effects of ezetimibe","volume":"4","author":"Stolk","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2007.06.010_bib8","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1331\/154434506778073637","article-title":"Safety issues with statin therapy","volume":"46","author":"Talbert","year":"2006","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"8A","key":"10.1016\/j.cld.2007.06.010_bib9","doi-asserted-by":"crossref","first-page":"77C","DOI":"10.1016\/j.amjcard.2005.12.014","article-title":"National Lipid Association Statin Safety Task Force Liver Expert Panel. An assessment of statin safety by hepatologists","volume":"97","author":"Cohen","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cld.2007.06.010_bib10","unstructured":"Drug Topics. Pharmacy facts and figures. 2006. Available at: http:\/\/www.drugtopics.com\/drugtopics\/article\/articleList.jsp?categoryId=7604. Accessed December 5, 2006."},{"issue":"7","key":"10.1016\/j.cld.2007.06.010_bib11","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.cgh.2006.04.020","article-title":"Statins for hyperlipidemia in patients with chronic liver disease: are they safe?","volume":"4","author":"Vuppalanchi","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.cld.2007.06.010_bib12","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/lt.20204","article-title":"Liver transplantation for acute liver failure from drug induced liver injury in the United States","volume":"10","author":"Russo","year":"2004","journal-title":"Liver Transpl"},{"issue":"12","key":"10.1016\/j.cld.2007.06.010_bib13","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/S0002-9149(02)02355-X","article-title":"The liver and lovastatin","volume":"89","author":"Tolman","year":"2002","journal-title":"Am J Cardiol"},{"issue":"12A","key":"10.1016\/j.cld.2007.06.010_bib14","doi-asserted-by":"crossref","first-page":"15E","DOI":"10.1016\/S0002-9149(00)00946-2","article-title":"Defining patient risks from expanded preventive therapies","volume":"85","author":"Tolman","year":"2000","journal-title":"Am J Cardiol"},{"issue":"8A","key":"10.1016\/j.cld.2007.06.010_bib15","doi-asserted-by":"crossref","first-page":"44C","DOI":"10.1016\/j.amjcard.2005.12.009","article-title":"Statin safety: lessons from new drug applications for marketed statins","volume":"97","author":"Jacobson","year":"2006","journal-title":"Am J Cardiol"},{"issue":"15","key":"10.1016\/j.cld.2007.06.010_bib16","doi-asserted-by":"crossref","first-page":"16J","DOI":"10.1016\/0002-9149(88)90003-3","article-title":"Preclinical evaluation of lovastatin","volume":"62","author":"MacDonald","year":"1998","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.1016\/j.cld.2007.06.010_bib17","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1600-0773.1990.tb00840.x","article-title":"Biochemical changes and morphological alterations of the liver in guinea-pigs after administration of simvastatin (HMG CoA reductase-inhibitor)","volume":"67","author":"Horsmans","year":"1990","journal-title":"Pharmacol Toxicol"},{"issue":"15","key":"10.1016\/j.cld.2007.06.010_bib18","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1001\/archinte.159.15.1811-a","article-title":"Atorvastatin-induced cholestatic hepatitis in a young woman with systemic lupus erythematosus","volume":"159","author":"Jimenez-Alonso","year":"1999","journal-title":"Arch Intern Med"},{"issue":"9166","key":"10.1016\/j.cld.2007.06.010_bib19","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/S0140-6736(99)00569-3","article-title":"Atorvastatin-induced acute hepatitis with absence of cross-toxicity with simvastatin","volume":"353","author":"Nakad","year":"1999","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.cld.2007.06.010_bib20","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1157\/13083248","article-title":"[Acute cholestatic hepatitis after atorvastatin reintroduction] [in Spanish; Case Report]","volume":"29","author":"de Castro","year":"2006","journal-title":"Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2007.06.010_bib21","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1592\/phco.24.1.150.34803","article-title":"Liver function test abnormalities and pruritis in a patient treated with atorvastatin: case report and review of the literature","volume":"24","author":"Gershovich","year":"2004","journal-title":"Pharmacotherapy"},{"issue":"8","key":"10.1016\/j.cld.2007.06.010_bib22","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1097\/00042737-200308000-00014","article-title":"Autoimmune hepatitis revealed by atorvastatin","volume":"15","author":"Pelli","year":"2003","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.cld.2007.06.010_bib23","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1007\/BF02088142","article-title":"Acute hepatitis induced by HMG-CoA reductase inhibitor, lovastatin","volume":"39","author":"Grimbert","year":"1994","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cld.2007.06.010_bib24","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/00000441-200502000-00002","article-title":"Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes","volume":"329","author":"Vuppalanchi","year":"2005","journal-title":"Am J Med Sci"},{"issue":"4","key":"10.1016\/j.cld.2007.06.010_bib25","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1345\/aph.1G462","article-title":"Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity","volume":"40","author":"Ricaurte","year":"2006","journal-title":"Ann Pharmacother"},{"issue":"9","key":"10.1016\/j.cld.2007.06.010_bib26","first-page":"339","article-title":"Simvastatin-diltiazem drug interaction resulting in rhabdomyolysis and hepatitis","volume":"94","author":"Kanathur","year":"2001","journal-title":"Tenn Med"},{"issue":"2","key":"10.1016\/j.cld.2007.06.010_bib27","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1023\/A:1005505827545","article-title":"Myositis, microvesicular hepatitis, and progression to cirrhosis from troglitazone added to simvastatin","volume":"46","author":"Caldwell","year":"2001","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cld.2007.06.010_bib28","first-page":"75","article-title":"Flutamide-induced hepatotoxicity with possible potentiation by simvastatin","volume":"51","author":"Ashar","year":"2003","journal-title":"J Assoc Physicians India"},{"issue":"5","key":"10.1016\/j.cld.2007.06.010_bib29","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1111\/j.1572-0241.1999.01091.x","article-title":"Acute cholestatic hepatitis associated with pravastatin","volume":"94","author":"Hartleb","year":"1999","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.cld.2007.06.010_bib30","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1592\/phco.24.6.584.34738","article-title":"Statins and liver toxicity: a meta-analysis","volume":"24","author":"de Denus","year":"2004","journal-title":"Pharmacotherapy"},{"issue":"12","key":"10.1016\/j.cld.2007.06.010_bib31","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1016\/j.bcp.2004.02.037","article-title":"Apoptotic injury in cultured human hepatocytes induced by HMG-CoA reductase inhibitors","volume":"67","author":"Kubota","year":"2004","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"10.1016\/j.cld.2007.06.010_bib32","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/00042737-200505000-00019","article-title":"Rosuvastatin-associated hepatitis with autoimmune features","volume":"17","author":"Wolters","year":"2005","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.cld.2007.06.010_bib33","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1161\/01.CIR.0000032466.44170.44","article-title":"American College of Cardiology. American Heart Association. National Heart, Lung and Blood Institute. ACC\/AHA\/NHLBI Clinical advisory on the use and safety of statins","volume":"106","author":"Pasternak","year":"2002","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.cld.2007.06.010_bib34","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2165\/00002018-200023030-00003","article-title":"Comparative tolerability of the HMG-CoA reductase inhibitors","volume":"23","author":"Farmer","year":"2000","journal-title":"Drug Saf"},{"issue":"20","key":"10.1016\/j.cld.2007.06.010_bib35","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1161\/01.CIR.0000017634.00171.24","article-title":"Safety and tolerability of pravastatin in long-term clinical trials: Prospective Pravastatin Pooling (PPP) project","volume":"105","author":"Pfeffer","year":"2002","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.cld.2007.06.010_bib36","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/S0168-8278(03)00464-1","article-title":"Fatal liver failure with atorvastatin","volume":"39","author":"Perger","year":"2003","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2007.06.010_bib37","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1191\/0961203303lu313cr","article-title":"Drug-induced lupus-like syndrome associated with severe autoimmune hepatitis","volume":"12","author":"Graziadei","year":"2003","journal-title":"Lupus"},{"issue":"8","key":"10.1016\/j.cld.2007.06.010_bib38","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1097\/00004836-200609000-00018","article-title":"Autoimmune hepatitis induced by statins","volume":"40","author":"Alla","year":"2006","journal-title":"J Clin Gastroenterol"},{"issue":"9","key":"10.1016\/j.cld.2007.06.010_bib39","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S0002-9343(01)00758-6","article-title":"Statins and cancer: a case of meta-uncertainty","volume":"110","author":"Guallar","year":"2001","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.cld.2007.06.010_bib40","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1001\/jama.1996.03530250059028","article-title":"Carcinogenicity of lipid-lowering drugs","volume":"275","author":"Newman","year":"1996","journal-title":"JAMA"},{"issue":"9436","key":"10.1016\/j.cld.2007.06.010_bib41","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(04)16936-5","article-title":"Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S)","volume":"364","author":"Strandberg","year":"2004","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.cld.2007.06.010_bib42","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/hep.20671","article-title":"Statins and hepatotoxicity: focus on patients with fatty liver","volume":"41","author":"Chalasani","year":"2005","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.cld.2007.06.010_bib43","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1016\/j.transproceed.2005.09.163","article-title":"Safety of statins when response is carefully monitored: a study of 336 heart recipients","volume":"37","author":"Marzoa-Rivas","year":"2005","journal-title":"Transplant Proc"},{"issue":"2","key":"10.1016\/j.cld.2007.06.010_bib44","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S1053-2498(01)00369-2","article-title":"Safety and efficacy of atorvastatin in heart transplant recipients","volume":"21","author":"Patel","year":"2002","journal-title":"J Heart Lung Transplant"},{"issue":"18","key":"10.1016\/j.cld.2007.06.010_bib45","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.2165\/00003495-200565180-00014","article-title":"Prolonged-release nicotinic acid: a review of its use in the treatment of dyslipidaemia","volume":"65","author":"McCormack","year":"2005","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.cld.2007.06.010_bib46","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1185\/030079906X89766","article-title":"Evaluation of the safety and tolerability of prolonged-release nicotinic acid in a usual care setting: the NAUTILUS study","volume":"22","author":"Vogt","year":"2006","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"10.1016\/j.cld.2007.06.010_bib47","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/0002-9343(92)90689-9","article-title":"Hepatotoxicity associated with sustained-release niacin","volume":"93","author":"Dalton","year":"1992","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.cld.2007.06.010_bib48","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0025-6196(12)61171-9","article-title":"Niacin-induced hepatitis: a potential side effect with low-dose time-release niacin","volume":"66","author":"Etchason","year":"1991","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"10.1016\/j.cld.2007.06.010_bib49","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/jama.1990.03450020093033","article-title":"Rechallenge with crystalline niacin after drug-induced hepatitis from sustained-release niacin","volume":"264","author":"Henkin","year":"1990","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.cld.2007.06.010_bib50","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1001\/jama.1990.03450020033012","article-title":"Acute hepatic failure associated with the use of low-dose sustained-release niacin","volume":"264","author":"Hodis","year":"1990","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.cld.2007.06.010_bib51","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/00004836-199404000-00037","article-title":"Niacin-induced hepatitis and thrombocytopenia after 10 years of niacin use","volume":"18","author":"Reimund","year":"1994","journal-title":"J Clin Gastroenterol"},{"issue":"3","key":"10.1016\/j.cld.2007.06.010_bib52","doi-asserted-by":"crossref","first-page":"253","DOI":"10.7326\/0003-4819-111-3-253","article-title":"Fulminant hepatic failure after ingestion of sustained-release nicotinic acid","volume":"111","author":"Mullin","year":"1989","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.cld.2007.06.010_bib53","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/00004836-198710000-00022","article-title":"Nicotinic acid-induced fulminant hepatic failure","volume":"9","author":"Clementz","year":"1987","journal-title":"J Clin Gastroenterol"},{"issue":"12","key":"10.1016\/j.cld.2007.06.010_bib54","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1517\/14656566.3.12.1763","article-title":"Niacin extended-release\/lovastatin: combination therapy for lipid disorders","volume":"3","author":"Moon","year":"2002","journal-title":"Expert Opin Pharmacother"},{"issue":"24","key":"10.1016\/j.cld.2007.06.010_bib55","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1093\/ajhp\/54.24.2815","article-title":"American Society of Health-System Pharmacists. ASHP Therapeutic Position Statement on the safe use of niacin in the management of dyslipidemias","volume":"54","year":"1997","journal-title":"Am J Health Syst Pharm"},{"issue":"4","key":"10.1016\/j.cld.2007.06.010_bib56","doi-asserted-by":"crossref","first-page":"321","DOI":"10.7863\/jum.1999.18.4.321","article-title":"Ultrasonographic findings in niacin-induced hepatitis","volume":"18","author":"Scheer","year":"1999","journal-title":"J Ultrasound Med"},{"issue":"2","key":"10.1016\/j.cld.2007.06.010_bib57","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/00004728-199903000-00026","article-title":"Effects of niacin therapy that simulate neoplasia: hepatic steatosis with concurrent hepatic dysfunction","volume":"23","author":"Kristensen","year":"1999","journal-title":"J Comput Assist Tomogr"},{"issue":"1","key":"10.1016\/j.cld.2007.06.010_bib58","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/00007611-199401000-00007","article-title":"Niacin-induced hepatotoxicity: unusual presentations","volume":"87","author":"Coppola","year":"1994","journal-title":"South Med J"},{"issue":"7","key":"10.1016\/j.cld.2007.06.010_bib59","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jama.1994.03520070031016","article-title":"Safety and side effects of sustained-release niacin","volume":"272","author":"Lavie","year":"1994","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.cld.2007.06.010_bib60","doi-asserted-by":"crossref","first-page":"252","DOI":"10.7326\/0003-4819-121-4-199408150-00003","article-title":"Efficacy and safety of controlled-release niacin in dyslipoproteinemic veterans","volume":"121","author":"Gray","year":"1994","journal-title":"Ann Intern Med"},{"issue":"12A","key":"10.1016\/j.cld.2007.06.010_bib61","doi-asserted-by":"crossref","first-page":"74U","DOI":"10.1016\/S0002-9149(98)00731-0","article-title":"Efficacy and safety of an extended-release niacin (Niaspan): a long-term study","volume":"82","author":"Capuzzi","year":"1998","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.cld.2007.06.010_bib62","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0002-9343(92)90018-7","article-title":"Hepatic toxicity of unmodified and time-release preparations of niacin","volume":"92","author":"Rader","year":"1992","journal-title":"Am J Med"},{"issue":"13 Suppl 2","key":"10.1016\/j.cld.2007.06.010_bib63","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1093\/ajhp\/60.suppl_2.S9","article-title":"Overview of niacin formulations: differences in pharmacokinetics, efficacy, and safety","volume":"60","author":"Pieper","year":"2003","journal-title":"Am J Health Syst Pharm"},{"issue":"10","key":"10.1016\/j.cld.2007.06.010_bib64","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/ajhp\/60.10.995","article-title":"Niacin for dyslipidemia: considerations in product selection","volume":"60","author":"McKenney","year":"2003","journal-title":"Am J Health Syst Pharm"},{"issue":"3","key":"10.1016\/j.cld.2007.06.010_bib65","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/00004836-199304000-00015","article-title":"Transient focal hepatic defects related to sustained-release niacin","volume":"16","author":"Lawrence","year":"1993","journal-title":"J Clin Gastroenterol"},{"issue":"9","key":"10.1016\/j.cld.2007.06.010_bib66","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1001\/jama.1994.03510330050033","article-title":"A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients","volume":"271","author":"McKenney","year":"1994","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.cld.2007.06.010_bib67","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1093\/carcin\/15.12.2847","article-title":"Effect of the peroxisome proliferators ciprofibrate and perfluorodecanoic acid on hepatic cell proliferation and toxicity in Sprague-Dawley rats","volume":"15","author":"Chen","year":"1994","journal-title":"Carcinogenesis"},{"issue":"1\u20132","key":"10.1016\/j.cld.2007.06.010_bib68","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.mrfmmm.2003.12.019","article-title":"Profiling of hepatic gene expression in rats treated with fibric acid analogs","volume":"549","author":"Cornwell","year":"2004","journal-title":"Mutat Res"},{"issue":"1","key":"10.1016\/j.cld.2007.06.010_bib69","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S0090-9556(24)14897-0","article-title":"Comparative metabolism and disposition of gemfibrozil in male and female Sprague-Dawley rats and Syrian golden hamsters","volume":"27","author":"Dix","year":"1999","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"10.1016\/j.cld.2007.06.010_bib70","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.amjcard.2004.06.033","article-title":"Risk of adverse events with fibrates","volume":"94","author":"Alsheikh-Ali","year":"2004","journal-title":"Am J Cardiol"},{"issue":"8","key":"10.1016\/j.cld.2007.06.010_bib71","first-page":"419","article-title":"[Acute hepatitis caused by gemfibrozil]","volume":"21","author":"Bustamante Balen","year":"1998","journal-title":"Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.cld.2007.06.010_bib72","first-page":"610","article-title":"[Cholestatic hepatitis caused by gemfibrozil]","volume":"93","author":"de Diego Lorenzo","year":"2001","journal-title":"Rev Esp Enferm Dig"},{"issue":"1","key":"10.1016\/j.cld.2007.06.010_bib73","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1385\/MO:23:1:121","article-title":"Drug-induced hepatitis in a patient with malignant melanoma treated with interferon alfa 2b adjuvantly who had been administered gemfibrozil in therapy","volume":"23","author":"Grubisic-Cabo","year":"2006","journal-title":"Med Oncol"},{"issue":"5","key":"10.1016\/j.cld.2007.06.010_bib74","first-page":"245","article-title":"Fenofibrate-induced acute cholestatic hepatitis","volume":"67","author":"Ho","year":"2004","journal-title":"J Chin Med Assoc"},{"issue":"5","key":"10.1016\/j.cld.2007.06.010_bib75","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/S0002-9149(97)00430-X","article-title":"Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia","volume":"80","author":"Athyros","year":"1997","journal-title":"Am J Cardiol"},{"issue":"18","key":"10.1016\/j.cld.2007.06.010_bib76","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1161\/01.CIR.0000164260.82417.3F","article-title":"Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans","volume":"111","author":"Landmesser","year":"2005","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.cld.2007.06.010_bib77","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1368-5031.2005.00565.x","article-title":"Efficacy and safety of ezetimibe co-administered with ongoing atorvastatin therapy in achieving low-density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease","volume":"59","author":"Cruz-Fernandez","year":"2005","journal-title":"Int J Clin Pract"},{"issue":"10","key":"10.1016\/j.cld.2007.06.010_bib78","first-page":"2081","article-title":"Ezetimibe\/simvastatin (Vytorin) for hypercholesterolemia","volume":"72","author":"Goldman-Levine","year":"2005","journal-title":"Am Fam Physician"},{"issue":"8","key":"10.1016\/j.cld.2007.06.010_bib79","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1185\/030079905X46386","article-title":"The effect of fluvastatin on the pharmacokinetics and pharmacodynamics of ezetimibe","volume":"21","author":"Reyderman","year":"2005","journal-title":"Curr Med Res Opin"},{"issue":"Pt 5","key":"10.1016\/j.cld.2007.06.010_bib80","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1258\/0004563054890105","article-title":"Drug-induced acute autoimmune hepatitis during combination therapy with atorvastatin and ezetimibe","volume":"42","author":"van Heyningen","year":"2005","journal-title":"Ann Clin Biochem"},{"issue":"3","key":"10.1016\/j.cld.2007.06.010_bib81","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1586\/14779072.4.3.283","article-title":"Colesevelam hydrochloride in the management of dyslipidemia","volume":"4","author":"Armani","year":"2006","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"4","key":"10.1016\/j.cld.2007.06.010_bib82","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1592\/phco.21.5.513.34501","article-title":"Colestipol-induced hepatotoxicity","volume":"21","author":"Sirmans","year":"2001","journal-title":"Pharmacotherapy"},{"issue":"3\u20134","key":"10.1016\/j.cld.2007.06.010_bib83","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1081\/DMR-200033475","article-title":"Detoxification of lithocholic acid, a toxic bile acid: relevance to drug hepatotoxicity","volume":"36","author":"Hofmann","year":"2004","journal-title":"Drug Metab Rev"},{"issue":"5","key":"10.1016\/j.cld.2007.06.010_bib84","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1002\/hep.21368","article-title":"Bile acids inhibit interleukin-6 signaling via gp130 receptor-dependent and -independent pathways in rat liver","volume":"44","author":"Graf","year":"2006","journal-title":"Hepatology"},{"issue":"17 Suppl","key":"10.1016\/j.cld.2007.06.010_bib85","article-title":"Torcetrapib combined with atorvastatin raises HDL-C, lowers LDL-C, and is well tolerated: results from a phase 2 dose-ranging clinical trial","volume":"112","author":"Thuren","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.cld.2007.06.010_bib86","unstructured":"Davidson M, McKenney J, Revkin J, et\u00a0al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor torcetrapib when administered with and without atorvastatin to subjects with a low level of high-density lipoprotein cholesterol [abstract 802]. In: Program and abstracts from the American College of Cardiology Annual Scientific Sessions 2005. Orlando (FL), March 6\u20139, 2005."},{"key":"10.1016\/j.cld.2007.06.010_bib87","unstructured":"Daley J. Pfizer scraps drug trial after deaths. The Independent [serial online]. December 4, 2006. Available at: http:\/\/news.independent.co.uk\/business\/news\/article2037520.ece. Accessed December 4, 2006."},{"key":"10.1016\/j.cld.2007.06.010_bib88","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1161\/01.ATV.0000121505.88326.d2","article-title":"High-density lipoprotein: a new potential therapeutic target for the prevention of cardiovascular disease","volume":"24","author":"Brewer","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cld.2007.06.010_bib89","unstructured":"FDA Statement. Pfizer stops all torcetrapib clinical trials in interest of patient safety. Available at: http:\/\/www.fda.gov\/bbs\/topics\/NEWS\/2006\/NEW01514.html. Accessed December 4, 2006."},{"issue":"8","key":"10.1016\/j.cld.2007.06.010_bib90","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1111\/j.1572-0241.2004.30159.x","article-title":"Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis","volume":"99","author":"Chalasani","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2007.06.010_bib91","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1053\/j.gastro.2004.02.015","article-title":"Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity","volume":"126","author":"Chalasani","year":"2004","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.cld.2007.06.010_bib92","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.cgh.2006.03.014","article-title":"Incidence of statin hepatotoxicity in patients with hepatitis C","volume":"4","author":"Khorashadi","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2007.06.010_bib93","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/hep.21248","article-title":"Statins and hepatic steatosis: perspectives from the Dallas Heart Study","volume":"44","author":"Browning","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2007.06.010_bib94","article-title":"Safety and efficacy of pravastatin 80 mg\/day in 320 hypercholesterolemic patients with compensated chronic liver disease (CLD): results of a prospective, randomized, double-blind, placebo-controlled study","volume":"130","author":"Lewis","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2007.06.010_bib95","article-title":"Lovastatin is not hepatotoxic to patients with pre-existing liver disease","volume":"130","author":"Avins","year":"2006","journal-title":"Gastroenterology"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326107000542?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326107000542?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T17:30:33Z","timestamp":1737394233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326107000542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8]]},"references-count":95,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,8]]}},"alternative-id":["S1089326107000542"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2007.06.010","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2007,8]]}}}